Simulations Plus Inc (SLP): AI Vision and Q2 Growth Analysis

Simulations Plus Inc (SLP) is advancing its strategy to integrate artificial intelligence into drug development by expanding its collaboration programs and enhancing its predictive modeling platforms, according to recent disclosures from the company and its financial reporting.

The company reported strong fiscal second-quarter results for the period ended January 31, 2026, with revenue reaching $28.4 million, a 22% increase compared to $23.3 million in the same quarter of the prior year. This growth was driven by higher demand for its ADMET Predictor software and increased activity in its collaboration services division, which supports pharmaceutical partners in early-stage drug discovery.

Simulations Plus emphasized that its AI-driven tools are designed to reduce the time and cost associated with identifying viable drug candidates by predicting absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties earlier in the development process. The company’s GastroPlus platform, which simulates drug behavior in human gastrointestinal systems, saw expanded licensing agreements during the quarter, particularly with mid-sized biotechnology firms seeking to optimize preclinical candidates.

In addition to software licensing, the company reported growth in its collaboration programs, where scientists work directly with pharmaceutical clients to apply simulation models to specific drug projects. These partnerships generated $9.1 million in revenue during the quarter, up from $7.4 million year-over-year, reflecting increased outsourcing of computational pharmacology tasks by drug developers aiming to improve experimental efficiency.

The company’s leadership highlighted that AI integration is not intended to replace laboratory testing but to prioritize compounds with the highest likelihood of success, thereby reducing late-stage failures. In a presentation to investors following the earnings release, CEO Walter S. Woltosz stated that the company’s models have contributed to advancing over 120 drug candidates into clinical trials since 2020, with a subset showing improved progression rates compared to industry averages.

Despite the positive financial performance, some analysts have questioned the scalability of Simulations Plus’s AI models beyond niche therapeutic areas. A Seeking Alpha analysis noted that while the company’s tools are well-established in small-molecule drug development, their application to biologics and complex modalities remains limited, potentially constraining long-term market expansion. The report also pointed to increasing competition from larger technology firms entering the AI-drug discovery space, which could pressure pricing and talent acquisition.

Simulations Plus continues to invest in research and development, allocating $4.2 million to R&D in the fiscal second quarter, representing 14.8% of quarterly revenue. The company said these funds support ongoing enhancements to its machine learning algorithms, expansion of its biological datasets, and validation of models against emerging clinical trial outcomes.

The company remains listed on the NASDAQ under the ticker SLP and has a market capitalization of approximately $1.1 billion as of mid-April 2026. It has not issued any forward-looking financial guidance beyond confirming that its fiscal year 2026 revenue is expected to grow in the low-to-mid teens percentage range, contingent on sustained demand for its software and collaboration services.

As pharmaceutical companies continue to seek ways to de-risk drug development pipelines, Simulations Plus positions its AI-powered simulation tools as a means to increase the efficiency of early-stage research. The company’s near-term focus remains on deepening existing partnerships, broadening its client base in the biotech sector, and refining its models to address a wider range of molecular targets and administration routes.